Regeneron Pharmaceuticals said on Tuesday the U.S. government signed a $450 million contract with the drugmaker to make and supply its potential double-antibody cocktail for Covid-19.
The cocktail, REGN-COV2, is in separate clinical trials assessing its effectiveness in preventing and treating Covid-19, the company said.
Regeneron signed the contract with the U.S. Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense. The doses manufactured under the project will be owned by the federal government.
